Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · page 29 of 37
The slide uses a stacked bar chart to visualize the additive clinical remission rates, noting a 22% delta between the individual components and the combination.
Pitch deck · comparison_table · compare_peers · dense density
Slide locked Sign in to view
Slide schematic 5/5
callout 2/2 chart 1/1 source-note 1/1 title 1/1
Components 5
primary primary bar-stacked source-note headline
Tools 2
Chartjunk Elimination slide · 70%
VEGA Combination Study (N=71/arm) showing 25% for Anti-TNF, 24% for Anti-IL23, and 47% for Combination (25% + 22% additive)
Comparison frame slide · 80%VEGA Combination Study (N=71/arm) showing 25% for Anti-TNF, 24% for Anti-IL23, and 47% for Combination (25% + 22% additive)
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1